Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Evorpacept by ALX Oncology for Oropharyngeal Cancer: Likelihood of Approval
Evorpacept is under clinical development by ALX Oncology and currently in Phase II for Oropharyngeal Cancer. According to GlobalData, Phase...
Evorpacept by ALX Oncology for Refractory Multiple Myeloma: Likelihood of Approval
Evorpacept is under clinical development by ALX Oncology and currently in Phase II for Refractory Multiple Myeloma. According to GlobalData,...
Evorpacept by ALX Oncology for Relapsed Multiple Myeloma: Likelihood of Approval
Evorpacept is under clinical development by ALX Oncology and currently in Phase II for Relapsed Multiple Myeloma. According to GlobalData,...
Risk adjusted net present value: What is the current valuation of ALX Oncology's Evorpacept?
Evorpacept is a fusion protein commercialized by ALX Oncology, with a leading Phase III program in Gastric Cancer. According to...
Risk adjusted net present value: What is the current valuation of ALX Oncology's Evorpacept?
Evorpacept is a fusion protein commercialized by ALX Oncology, with a leading Phase III program in Adenocarcinoma Of The Gastroesophageal...